

Leukaemia AML and CLL Treatments

Reference Number: RDF2030-23

Date of Response: 28/11/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

To the Royal Devon University Healthcare NHS Foundation Trust,

Please see below a Freedom of Information request. Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

Patients with acute myeloid leukaemia (AML)

- How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?*

Answer: Please see table below. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

Azacitidine monotherapy	≤5
Low dose cytarabine (LoDAC) monotherapy	≤5
Venetoclax + azacitidine	≤5
Venetoclax + LoDAC	≤5
Ivosidenib	Nil
Intensive chemotherapy-based regime	11
Other	123

- How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?
Note: this should only include patients who have started first-line treatment during the 6-month window*

Answer: Please see table below.

Azacitidine monotherapy	Nil
Low dose cytarabine (LoDAC) monotherapy	≤5
Venetoclax + azacitidine	≤5
Venetoclax + LoDAC	≤5
Ivosidenib	Nil
Intensive chemotherapy-based regime	8
Other	44

3. (a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?

Answer: 7.

Patients with chronic lymphocytic leukaemia (CLL)

4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include patients who started treatment prior to the 6-month window

Answer: 26.

5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment during the 6-month window

Answer: 14.